Alvotech SEC filings ALVO
Alvotech has 302 filings in SEC EDGAR's recent list, going back to Dec 20, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 20, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jun 16, 2026 | — |
| FWP | Free writing prospectus | Jun 16, 2026 | — |
| FWP | Free writing prospectus | Jun 15, 2026 | — |
| 424B5 | Prospectus supplement | Jun 15, 2026 | — |
| F-3ASR | Filing | Jul 28, 2025 | — |
| 424B3 | Prospectus | Aug 29, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Aug 21, 2024 | — |
| 424B5 | Prospectus supplement | Jun 14, 2024 | — |
| F-3 | Shelf registration (foreign issuer) | Oct 20, 2023 | — |
| 424B3 | Prospectus | Jul 24, 2023 | — |
| 424B3 | Prospectus | Jul 24, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Jul 14, 2023 | — |
| POS AM | Filing | Jul 14, 2023 | — |
| 424B3 | Prospectus | Jun 29, 2023 | — |
| 424B3 | Prospectus | Jun 6, 2023 | — |
| 424B3 | Prospectus | May 24, 2023 | — |
| 424B3 | Prospectus | Apr 14, 2023 | — |
| POS AM | Filing | Mar 13, 2023 | — |
| 424B3 | Prospectus | Feb 10, 2023 | — |
| 424B3 | Prospectus | Feb 10, 2023 | — |
| 424B3 | Prospectus | Feb 9, 2023 | — |
| 424B3 | Prospectus | Feb 9, 2023 | — |
| 424B3 | Prospectus | Jan 23, 2023 | — |
| 424B3 | Prospectus | Jan 23, 2023 | — |
| 424B3 | Prospectus | Jan 11, 2023 | — |
| 424B3 | Prospectus | Jan 11, 2023 | — |
| 424B3 | Prospectus | Jan 6, 2023 | — |
| 424B3 | Prospectus | Jan 6, 2023 | — |
| 424B3 | Prospectus | Dec 22, 2022 | — |
| 424B3 | Prospectus | Dec 22, 2022 | — |
| 424B3 | Prospectus | Dec 16, 2022 | — |
| 424B3 | Prospectus | Dec 16, 2022 | — |
| 424B3 | Prospectus | Dec 8, 2022 | — |
| 424B3 | Prospectus | Dec 8, 2022 | — |
| 424B3 | Prospectus | Dec 1, 2022 | — |
| 424B3 | Prospectus | Dec 1, 2022 | — |
| 424B3 | Prospectus | Nov 17, 2022 | — |
| 424B3 | Prospectus | Nov 17, 2022 | — |
| 424B3 | Prospectus | Oct 19, 2022 | — |
| 424B3 | Prospectus | Oct 19, 2022 | — |
| 424B3 | Prospectus | Oct 17, 2022 | — |
| 424B3 | Prospectus | Oct 17, 2022 | — |
| 424B3 | Prospectus | Oct 12, 2022 | — |
| 424B3 | Prospectus | Oct 12, 2022 | — |
| 424B3 | Prospectus | Sep 23, 2022 | — |
| 424B3 | Prospectus | Sep 23, 2022 | — |
| 424B3 | Prospectus | Sep 21, 2022 | — |
| 424B3 | Prospectus | Sep 21, 2022 | — |
| F-1/A | Filing | Sep 14, 2022 | — |
| F-1/A | Filing | Sep 13, 2022 | — |
| S-8 | Employee stock plan registration | Aug 15, 2022 | — |
| F-1/A | Filing | Jul 27, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Jul 22, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Jul 14, 2022 | — |
| 424B3 | Prospectus | May 10, 2022 | — |
| F-4/A | Filing | May 10, 2022 | — |
| F-4/A | Filing | May 2, 2022 | — |
| F-4/A | Filing | Apr 19, 2022 | — |
| F-4/A | Filing | Apr 4, 2022 | — |
| F-4/A | Filing | Mar 14, 2022 | — |
| F-4/A | Filing | Feb 7, 2022 | — |
| F-4 | Filing | Dec 20, 2021 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALVO (Nasdaq), ALVOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Luxembourg
- Headquarters
- Luxembourg, Luxembourg
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1898416
- Former names
- Alvotech Lux Holdings S.A.S. (until May 2, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.